Home / Health / Massive Price Cuts on 543 Cancer Drugs in India
Massive Price Cuts on 543 Cancer Drugs in India
28 Oct
Summary
- 543 anti-cancer drug brands see revised maximum retail prices.
- Trade margins capped at 30% for identified non-scheduled drugs.
- Revised rates for cancer medicines are effective from November 9, 2026.
India's National Pharmaceutical Pricing Authority (NPPA) has announced revised Maximum Retail Prices (MRPs) for 543 brands of anti-cancer drugs, with new rates effective November 9, 2026. This significant price reduction aims to alleviate the financial strain on cancer patients.
Several crucial cancer medications have experienced substantial price cuts. For instance, the cost of Anastrozole, used for breast cancer, has fallen dramatically. Azacitidine injections are now priced considerably lower, as are Bevacizumab and Dasatinib. Denosumab injections also feature reduced pricing.
The government's decision to revise these prices stems from the introduction of Trade Margin Rationalisation (TMR) for 137 non-scheduled anti-cancer drugs. Under this policy, trade margins are capped at 30% of the MRP, a measure intended to make treatments more affordable.
These revised prices are effective from November 9, 2026. The NPPA's updated list, based on company submissions until October 27, 2026, will be continuously updated. Patients are advised to verify the revised prices for their specific prescribed medications.
